Design of aromatic inhibitors of influenza virus neuraminidase.
Structure-based drug design, a terminology used to describe rational drug design by complementing the structure, spatially and chemically, of the target macromolecule, is rapidly developing as one of the innovative approaches to drug discovery. A growing volume of protein structure data and new techniques of protein structure determination make this all possible. The method of structure-based drug design and a specific example of the design of influenza virus neuraminidase is briefly presented. A whole new class of influenza virus neuraminidase inhibitors has been designed that can potentially be developed as antiinfluenza drugs.
Luo
M
M
Center for Macromolecular Crystallography, Department of Microbiology, University of Alabama at Birmingham, 35294, USA.
Air
G M
GM
Brouillette
W J
WJ
D000998:Antiviral Agents / Q000138:chemical synthesis*; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis*; D009439:Neuraminidase / Q000037:antagonists & inhibitors* / Q000737:chemistry; D009975:Orthomyxoviridae / Q000187:drug effects* / Q000201:enzymology
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D009439:Neuraminidase